Quest offers its BRCAvantage test on the MiSeq, has other oncology and neurology NGS tests in development, and is converting all its Sanger tests to NGS.
The saliva-based test identifies mutations in the BRCA1 and BRCA2 genes with 99.99 percent accuracy.
The institute will work with Kailos Genetics to provide free mutation testing for BRCA1/2 and 17 other genes linked to greater risk of breast and ovarian cancer.
Through its agreement with Quest Diagnostics, the company plans to launch a BRCA1/2 test, followed by tests for Lynch syndrome and HPV.
Although male breast cancer is uncommon, and in the past men haven't been readily tested for inherited risk mutations, more men are speaking out about their experiences.
For every paid myBRCA test performed, the startup said that it will donate a free test.
Data presented at the meeting helped better define the potential benefits and risks of broad panel-based tests for hereditary cancer genes.
Opko plans to leverage BRL's national marketing, sales, and distribution resources to enhance the sale of its blood-based 4Kscore test for aggressive prostate cancer.
The company has established a streamlined workflow that customizes and automates key steps of the sample prep process.
In joining forces to support BRCAShare, Quest and LabCorp are taking on Myriad Genetics, which maintains a proprietary database with more than 1 million test results.
The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.
A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.
Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.
In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.